A Ring Or Polycyclo Ring System In A Substituent E Is Attached Indirectly To The Carboxamide Nitrogen Or To An Amino Nitrogen In Substituent E By Acyclic Nonionic Bonding Patents (Class 514/630)
  • Publication number: 20120316245
    Abstract: New co-crystal of agomelatine composed of: agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide of formula (I) and an organic acid. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.
    Type: Application
    Filed: June 8, 2012
    Publication date: December 13, 2012
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Philippe Letellier, Michael Lynch, Jean-Manuel Pean
  • Publication number: 20120309838
    Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Obsessive-Compulsive Disorder (OCD).
    Type: Application
    Filed: February 10, 2011
    Publication date: December 6, 2012
    Applicant: Les Laboratoires Servier
    Inventors: Laurence Laigle, Elisabeth Mocaer, Mark Millan
  • Publication number: 20120309837
    Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Type: Application
    Filed: December 23, 2011
    Publication date: December 6, 2012
    Inventors: Partha S. Banerjee, Imtiaz A. Chaudry, Stephen Pham
  • Publication number: 20120302528
    Abstract: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend.
    Type: Application
    Filed: August 6, 2012
    Publication date: November 29, 2012
    Applicant: ETHICON, INC.
    Inventors: Sasa ANDJELIC, Benjamin D. FITZ, Jianguo Jack ZHOU
  • Patent number: 8318813
    Abstract: The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: November 27, 2012
    Assignee: LCS Group, LLC
    Inventor: Louis Sanfilippo
  • Patent number: 8314270
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: November 20, 2012
    Assignee: Abbott Laboratories
    Inventors: James T. Link, Qi Shuai, Martin Winn, Hong Yong
  • Publication number: 20120288562
    Abstract: The present invention relates to new acid resistant hard pharmaceutical capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration of pharmaceuticals, veterinary products, food and dietary supplements to humans or animals. The capsules of the invention are obtained by aqueous compositions comprising a water soluble film forming polymer and gellan gum in a mutual weight ratio of 4 to 15 weight parts of gellan gum for 100 weight parts of film forming polymer.
    Type: Application
    Filed: September 14, 2010
    Publication date: November 15, 2012
    Inventors: Dominique Nicolas Cade, Xiongwei David He
  • Publication number: 20120282335
    Abstract: This invention relates to rapidly dispersing microgranules comprising at least one sugar alcohol or saccharide, at least one super disintegrant, and a pharmaceutically acceptable additive with multi-functionality (e.g., starch acting as a binder, disintegrant, diluent/filler, glidant, etc) at a low level, which can be formed by not only eliminating a wet milling step but also avoiding an extensive dry milling step.
    Type: Application
    Filed: December 2, 2011
    Publication date: November 8, 2012
    Applicant: Aptalis Pharmatech Inc.
    Inventors: Gopi M. Venkatesh, Vijaya Swaminathan, Jin-Wang Lai, James M. Clevenger
  • Publication number: 20120283205
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Application
    Filed: February 7, 2012
    Publication date: November 8, 2012
    Inventors: Neil P. DESAI, Patrick Soon-Shiong, Vuong Trieu
  • Publication number: 20120269889
    Abstract: A non-gelatin encapsulation system for liquid filled soft capsules, by nature of the carrier, the cationic-ionic balance of the carrier and the active ingredients, or the concentration of the active ingredients and excipients, are difficult or impossible to commercially encapsulate in gelatin capsules. In particular, the system is adapted for the encapsulation of highly basic, or alkaline, fills. The system provides for a predominantly starch and gelling carrageenan based shell, which displays high resistance to both concentrated fills and to alkaline fills, in particular, to those fills which contain the salt or salts of weak acids and strong bases.
    Type: Application
    Filed: July 6, 2012
    Publication date: October 25, 2012
    Applicant: R.P. SCHERER TECHNOLOGIES, LLC
    Inventors: Keith E. Tanner, Rickey S. Shelley, Norman S. Stroud, Elizabeth Youngblood
  • Publication number: 20120270901
    Abstract: Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5, and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: December 8, 2011
    Publication date: October 25, 2012
    Applicant: Aquinox Pharmaceuticals Inc.
    Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
  • Publication number: 20120251623
    Abstract: In one aspect, the present invention features a method of administering an active ingredient, said method comprising chewing an oral dosage form comprising a texture masked particle, said texture masked particle comprising a) a core containing an active ingredient; b) a first coating layer comprised of a taste masking agent that substantially covers the core, wherein said taste masking agent is comprised of an insoluble film forming polymer and a non-enteric, water soluble polymer; and c) a second coating layer on the surface of the first coating layer.
    Type: Application
    Filed: June 12, 2012
    Publication date: October 4, 2012
    Inventors: Narendra Parikh, Daniel McTeigue, David W. Wynn, Ravivaj S. Pillai
  • Publication number: 20120252901
    Abstract: Agomelatine crystal, which is a drug for treating depression, and pharmaceutical compositions thereof are provided. The X-ray powder diffraction spectra of such agomelatine crystal, which is irradiated by Cu-K? and showed by 2?(degree), has characteristic diffraction peaks at 12.84, 13.84, 16.14, 18.56, 19.12, 20.86, 21.20, 23.84; its IR absorption pattern has characteristic absorption peaks at about 3234, 3060, 2940, 1638, 1511, 1436, 1249, 1215, 1184, 1032, 908, 828, 755, 588 cm-1, and its DSC endothermic transition temperature is 97.6° C. The use of the agomelatine crystal as an active ingredient in preparing a medicament for the treatment of depression is also provided.
    Type: Application
    Filed: December 13, 2010
    Publication date: October 4, 2012
    Applicant: TIANJIN TAIPU PHARMACEUTICAL SCIENCE & TECHNOLOGY DEVELOPMENT CO., LTD
    Inventors: Jianqiang Zhu, Qingson Tian, Jian Zhao
  • Publication number: 20120244097
    Abstract: A reversely thermo-reversible hydrogel composition comprising a water soluble block copolymer comprising at least two blocks of polyethylene oxide and at least one block of polypropylene oxide, and at least one associative gelling adjuvant having water solubility less than 0.5 g/100 ml, preferably less than 0.3 g/100 ml at 20° C., and being capable of forming water soluble inter-molecular complexes with the water soluble block copolymer in water. The hydrogel composition exhibits improved gelling efficiency, enhanced solubility and/or stability for water sparely soluble and insoluble pharmaceutical agents. The hydrogel compositions are useful in a variety of pharmaceutical and cosmetic products and applications, such as esophageal, otic, vaginal, rectal, ophthalmic, treatments of disorders and imperfections of the skin, and treating and/or preventing alopecia and restoring and/or promoting hair growth.
    Type: Application
    Filed: March 21, 2012
    Publication date: September 27, 2012
    Applicant: Broda Technologies Co., Ltd.
    Inventors: Shao Xiang Lu, Jeffrey Lu, Letian Liu
  • Publication number: 20120237574
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.
    Type: Application
    Filed: June 4, 2012
    Publication date: September 20, 2012
    Applicant: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Publication number: 20120225912
    Abstract: The invention relates to colchicine derivatives, methods and uses thereof for treatment of cancer.
    Type: Application
    Filed: July 30, 2010
    Publication date: September 6, 2012
    Inventors: Jack Tuszynski, Jonathan Y. Mane, John Torin Huzil, Boguslaw Tomanek, Dorota Bartusik
  • Patent number: 8252520
    Abstract: The present invention provides methods and compounds for inhibiting HEC1 activity for the treatment of diseases involving cell hyperproliferation, e.g. cancer. The present invention also provides methods of identifying compounds for inhibiting HEC1 activity.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: August 28, 2012
    Assignee: Taivex Therapeutics Corporation
    Inventors: Wen-Hwa Lee, Phang-Lang Chen, Yumay Chen
  • Patent number: 8252957
    Abstract: Process for obtaining the crystalline form V of the compound of formula (I):
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: August 28, 2012
    Assignee: Les Laboratoires Servier
    Inventors: Damien Martins, Gerard Coquerel, Julie Linol, Pascal Langlois
  • Publication number: 20120214852
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Application
    Filed: November 8, 2011
    Publication date: August 23, 2012
    Applicant: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
  • Publication number: 20120214785
    Abstract: The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: August 17, 2011
    Publication date: August 23, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Gerald Juergen ROTH, Martin FLECK, Niklas HEINE, Joerg KLEY, Thorsten LEHMANN-LINTZ, Heike NEUBAUER, Bernd NOSSE
  • Publication number: 20120213827
    Abstract: A process for controlling the crystallization of certain hydrophobic active pharmaceutical ingredients (APIs) from a supercooled liquid state by hot-melt extrusion processing is described. Also described is a pharmaceutical composition comprising a solid crystalline dispersion of a cholesterol ester transfer protein inhibitor in a hydrophilic excipient matrix. In the process of the present invention, the API is fed to an extrusion system in a crystalline state contemporaneously with carrier excipients where it is first converted to a non-crystalline state by the application of heat and then subsequently recrystallized in-situ by the removal of heat and application of shear. Recrystallization of the API is controlled by carrier formulation design and the hot-melt extrusion process parameters; i.e. barrel temperature profile, feed rate, etc.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Inventors: Ashish Chatterji, Dipen Desai, Dave Alan Miller, Harpreet K. Sandhu, Navnit H. Shah
  • Publication number: 20120208891
    Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Type: Application
    Filed: April 24, 2012
    Publication date: August 16, 2012
    Inventor: Matthew W. Davis
  • Publication number: 20120178757
    Abstract: A method is provided for the prevention of cancer metastasis in a patient comprising administering an adrenergic receptor antagonist to a patient in need thereof. The invention also includes an adrenergic receptor antagonist for use in the prevention of tumour recurrence in a patient. Also provided is a kit of parts for use in such methods comprising an adrenergic receptor antagonist, and an administration vehicle. A method is further included for identifying a patient at risk of developing cancer comprising the step of assaying for levels of expression of adrenergic receptor genes and proteins in said patient.
    Type: Application
    Filed: December 8, 2011
    Publication date: July 12, 2012
    Applicant: NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST
    Inventor: Desmond George Powe
  • Publication number: 20120172340
    Abstract: Methods for identifying selective activators of SIRT5 and/or SIRT1 and methods for using these selective activators in the modulation of SIRT5 and/or SIRT1 are provided.
    Type: Application
    Filed: October 7, 2010
    Publication date: July 5, 2012
    Applicant: BIOMOL International L.P.
    Inventors: Konrad T. Howitz, Robert E. Zipkin
  • Publication number: 20120171296
    Abstract: Provided is a solid preparation which rapidly disintegrates in the presence of saliva or a small amount of water in the oral cavity, particularly, a rapidly disintegrating solid preparation useful as an orally-disintegrating solid preparation. Specifically provided is a rapidly disintegrating solid preparation containing coated granules wherein saccharide or sugar alcohol having an average particle size of not less than 75 ?m and a high dissolution rate is coated with cellulose, and a rapidly disintegrating solid preparation containing a) an active ingredient, b) saccharide or sugar alcohol having an average particle size of not less than 400 ?m, c) cellulose and d) a disintegrant.
    Type: Application
    Filed: March 14, 2012
    Publication date: July 5, 2012
    Inventors: Akiko OOKAWA, Yasushi IMADA, Yasunari SHINKAI, Hideaki MATSUMOTO
  • Publication number: 20120156259
    Abstract: The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.
    Type: Application
    Filed: July 30, 2010
    Publication date: June 21, 2012
    Applicant: ASCENDIS PHARMA A/S
    Inventors: Harald Rau, Ulrich Hersel, Mathias Krusch, Dirk Vetter, Tobias Voigt
  • Publication number: 20120156261
    Abstract: There has been a need for an orally rapidly disintegrating tablet which has a good texture and taste in the oral cavity, such a sufficient hardness as not giving any worry of being chipped or dusted during production or transportation and good disintegrating properties in the oral cavity and can sustain a sufficient hardness even under humid conditions after opening. Disclosed are a disintegrating particle composition which is prepared by dispersing, in the presence of water, mannitol, xylitol, an inorganic excipient, a disintegrating agent and carmellose and drying, and an orally rapidly disintegrating tablet which comprises said disintegrating particle composition, an active substance and a disintegrating agent. The disintegrating tablet has a good texture and taste, an appropriate hardness and good disintegrating properties and can sustain a sufficient hardness under humid conditions.
    Type: Application
    Filed: August 11, 2010
    Publication date: June 21, 2012
    Inventors: Keiichi Fujiwara, Tadashi Fukami, Haruka Koizumi
  • Publication number: 20120129894
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Application
    Filed: May 19, 2011
    Publication date: May 24, 2012
    Applicant: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
  • Publication number: 20120122823
    Abstract: Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.
    Type: Application
    Filed: September 13, 2011
    Publication date: May 17, 2012
    Applicant: Bev-RX. Inc.
    Inventor: Kyle A. Reed
  • Publication number: 20120122938
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 17, 2012
    Applicant: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
  • Publication number: 20120115781
    Abstract: Provided is a method for evaluating test agents as candidates for treating prostatic diseases, including benign prostatic hyperplasia and androgen dependent and androgen independent prostate cancer. The method comprises providing a mouse comprising a human prostate primary xenograft, where the xenograft contains blood vessels that include human endothelial cells, initiating androgen deprivation in the mouse, administering to the mouse a test agent within a period of 1-7 days after initiating the androgen deprivation, and determining a reduction in human epithelial cells in the xenografts and/or a reduction in number of the endothelial cells or blood vessels in the xenograft. Also provided is a method for treating an individual for human prostate cancer or benign prostatic hyperplasia.
    Type: Application
    Filed: September 12, 2011
    Publication date: May 10, 2012
    Inventors: Gary J. Smith, Howard M. Reisner, Danny R. Gray, Wendy Huss
  • Publication number: 20120088837
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.
    Type: Application
    Filed: December 8, 2011
    Publication date: April 12, 2012
    Inventors: Robert Greenhouse, Ralph New Harris, III, Saul Jaime-Figueroa, James M. Kress, David Bruce Repke, Russell Stephen Stabler
  • Publication number: 20120077764
    Abstract: Novel formulations containing a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol, and methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bovine respiratory disease.
    Type: Application
    Filed: September 2, 2011
    Publication date: March 29, 2012
    Inventors: Keith A. FREEHAUF, Allan Weingarten, Robert D. Simmons, Kanwal Jit Varma
  • Patent number: 8134029
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: March 13, 2012
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Thomas Jerussi, Qun Kevin Fang, Mark G. Currie
  • Publication number: 20120059054
    Abstract: Described are matrix binders comprising copolymers based on amino-containing polymers, as well as their use in preparing active compound-containing granules and administration forms The copolymers having basic amino groups can be obtained by radical polymerization of: a) N,N-diethylaminoethyl methacrylate, and b) at least one radically polymerizable compound, selected from esters of ?,?-ethylenically unsaturated mono- and dicarboxylic acids with C1-C8 alkanols.
    Type: Application
    Filed: September 6, 2011
    Publication date: March 8, 2012
    Applicant: BASF SE
    Inventors: Karl Kolter, Maximilian Angel
  • Publication number: 20120053246
    Abstract: Provided herein is a highly pure arformoterol tartrate or an amorphous form thereof substantially free of desformyl impurity, 2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]aniline, process for the preparation thereof, and pharmaceutical compositions comprising the highly pure arformoterol tartrate substantially free of the desformyl impurity.
    Type: Application
    Filed: August 23, 2011
    Publication date: March 1, 2012
    Applicant: ACTAVIS GROUP PTC EHF
    Inventors: Anant Kishanrao Jagtap, Nandkumar Gaikwad, Nikhil Trivedi, Nitin Sharadchandra Pradhan
  • Publication number: 20120035267
    Abstract: The invention relates to an aqueous pharmaceutical composition, preferably an infusion solution, for parenteral administration which contains paracetamol and has an electrical conductivity of not more than 200 ?S cm?1.
    Type: Application
    Filed: April 19, 2010
    Publication date: February 9, 2012
    Applicant: Fresenius Kabi Deutschland GmbH
    Inventors: David Dasberg, Georg Achleitner, Christiane Aichholzer
  • Publication number: 20120027856
    Abstract: A pharmaceutical product containing an active pharmaceutical ingredient and having a controllable release of the active pharmaceutical ingredient. The pharmaceutical product comprises yeast that is capable of fermentation. The carbon dioxide production of the fermentation releases the active pharmaceutical ingredient from the pharmaceutical product.
    Type: Application
    Filed: August 21, 2008
    Publication date: February 2, 2012
    Applicant: LTS Lohmann Therapie-Systeme AG
    Inventors: Bodo Asmussen, Christiane Schiller, Werner Weitschies, Grzegorz Garbacz, Mahmoud A. Omer-Adam, Stefan Nagel
  • Publication number: 20120028912
    Abstract: The present invention features compounds useful for and methods for preventing or inhibiting the binding of bromodomains to acetyl-lysine residues of proteins and methods for treating HIV infection and HIV related disease.
    Type: Application
    Filed: November 2, 2009
    Publication date: February 2, 2012
    Inventors: Ming-Ming Zhou, Aneel K. Aggarwal, Melanie Ott, Eric Verdin
  • Publication number: 20120015031
    Abstract: A gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one opioid, at least one form of acetaminophen, optionally an opioid antagonist and at least one pharmaceutically acceptable excipient, which dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. Also provided is a method of treating pain by administering the dosage form to a patient in need thereof. The acetaminophen is either in slow release form or in immediate release form or as combination of both.
    Type: Application
    Filed: July 13, 2011
    Publication date: January 19, 2012
    Applicant: Grunenthal GmbH
    Inventor: Ramesh SESHA
  • Publication number: 20120004269
    Abstract: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Application
    Filed: August 3, 2011
    Publication date: January 5, 2012
    Applicant: Acucela Inc.
    Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Jennifer Gage, Feng Hong
  • Publication number: 20120004313
    Abstract: The invention provides a new crystalline form of agomelatine, preparation and use thereof. The X-ray powder diffraction diagram of the agomelatine crystalline form shows main peaks at the diffraction angles 2? 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° and 31.93°. Said new crystalline form is characterized by high purity, stability and good reproducibility, and thus is advantageous for the pharmaceutical formulation. In addition, the stability and solubility of said crystalline form are also superior over the several existing crystalline forms.
    Type: Application
    Filed: March 9, 2010
    Publication date: January 5, 2012
    Inventors: Hanbin Shan, Peng Zhang, Zhedong Yuan, Xudong Jiang, Yu Huang, Hubo Wang, Xufeng Cao, Xingdong Cheng, Xiong Yu
  • Publication number: 20120003316
    Abstract: This invention relates to a multi-configured, transmucosal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which has a single monolithic/heterogeneous layer or a plurality of such layers. The dosage form is suitable for the delivery of one or more pharmaceutical compositions via the buccal, sublingual, rectal, vaginal or transmucosal delivery route in a human or animal body. It provides for selected delivery profiles resulting from, but not limited to, a porosity-enabled composite matrix of one or more layers/components of the pharmaceutical composition/s. The invention also provides for a method of manufacturing said transmucosal pharmaceutical dosage form in a plurality of configurations.
    Type: Application
    Filed: June 3, 2009
    Publication date: January 5, 2012
    Inventors: Deshika Reddy, Oluwatoyin Ayotomilola Adeleke, Viness Pillay, Yahya Choonara
  • Publication number: 20120003158
    Abstract: The present invention provides various biomarkers of inflammatory bowel disease, including biomarkers for Crohn's disease and biomarkers for Ulcerative colitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of inflammatory bowel disease, methods for distinguishing between inflammatory bowel diseases, methods of determining predisposition to inflammatory bowel disease, methods of monitoring progression/regression of inflammatory bowel disease, methods of assessing efficacy of compositions for treating inflammatory bowel disease, methods of screening compositions for activity in modulating biomarkers of inflammatory bowel disease, methods of treating inflammatory bowel disease, as well as other methods based on biomarkers of inflammatory bowel disease.
    Type: Application
    Filed: April 8, 2011
    Publication date: January 5, 2012
    Inventors: Danny ALEXANDER, Jeffrey SHUSTER, Joshua KORZENIK, Garrett ZELLA
  • Publication number: 20110319492
    Abstract: The present invention features a process for making tablets containing one or more pharmaceutically active agent(s) and one or more binder(s), the method including the steps of (i) applying energy to a powder blend comprising the pharmaceutically active agent(s) and the binder(s) for a sufficient period of time to activate the binder(s) within the powder blend and (ii) forming a predetermined amount of the energy-applied powder blend into the tablets.
    Type: Application
    Filed: March 21, 2011
    Publication date: December 29, 2011
    Inventors: Joseph R. Luber, Christopher E. Szymczak, Frank J. Bunick, Harry S. Sowden, Leo B. Kriksunov
  • Publication number: 20110318351
    Abstract: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.
    Type: Application
    Filed: September 12, 2011
    Publication date: December 29, 2011
    Inventor: Ivan Bergstein
  • Publication number: 20110301243
    Abstract: The present invention is directed to a novel method for reducing intrapatient variability in pharmaceutically active agent which is suitably not absorbed in the stomach, such as paracetamol, containing formulations in patients having gastric dysmotility, or a method of improving analgesia in a diabetic patient, or improving absorption of an active agent is a patient with gastric dysmotility, which methods comprises administering orally to said patient in need thereof a pharmaceutical dosage form comprising a first active agent, calcium carbonate, at least one first binding agent, and at least one disintegrating agent as intragranular components in the form of a granulate, and as an extragranular component at least one hydrophilic colloid, an optionally a second binding agent, calcium carbonate, a super disintegrant, and a second active agent.
    Type: Application
    Filed: July 29, 2009
    Publication date: December 8, 2011
    Inventors: Geoffrey Douglas Clarke, Timothy James Grattan, Ian Burnett
  • Patent number: 8071651
    Abstract: Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is —CH2—; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, R2 is C1-6alkyl or C3-6cycloalkyl; R3 is independently of one another H, C1-6alkyl, C1-6alkoxycarbonyl or C1-6alkanoyl; R4 is C2-6alkenyl, C1-6alkyl, unsubstituted or substituted aryl-C1-6alkyl or C3-8cycloalkyl; R5 is -Lm-R6; L is C1-6alkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; R6 is a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: December 6, 2011
    Assignee: Novartis AG
    Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Stefan Stutz, Aleksandar Stojanovic, Christiane Marti, Dirk Behnke, Stjepan Jelakovic
  • Publication number: 20110293558
    Abstract: The invention in some aspects relates to methods, devices and compositions for evaluating material properties, such as mechanical and rheological properties of substances, particularly biological substances, such as cells, tissues, and biological fluids. In some aspects, the invention relates to methods, devices and compositions for evaluating material properties of deformable objects, such as cells. In further aspects, the invention relates to methods, devices and compositions for diagnosing and/or characterizing disease based on material properties of biological cells.
    Type: Application
    Filed: March 21, 2011
    Publication date: December 1, 2011
    Applicant: Massachusetts Institute of Technology
    Inventors: Subra Suresh, Jianzhu Chen, Irene Yin-Ting Chang
  • Publication number: 20110294830
    Abstract: The present invention provides a nitrogen-containing compound represented by formula (I1) (in formula (I1), R0 represents a nitro group or the like, Z represents an optionally substituted aryl group or the like, R3 represents a hydrogen atom or the like, Y represents a nitro group or the like, n represents an integer of 0 to 3, D represents an optionally substituted 5-membered to 8-membered hydrocarbon ring group or heterocyclic group having or not having a substituent other than substituent X, X represents a group represented by formula (II-1) (in formula (II-1), R1 and R2 respectively and independently represent a hydrogen atom or the like), A represents a carbon atom or the like, n1 represents an integer of 0 to 2) or a salt thereof, and an insecticide, miticide, sanitary insect pest control agent, or harmful organism control agent including as an active ingredient thereof the nitrogen-containing compound or the salt thereof.
    Type: Application
    Filed: February 5, 2010
    Publication date: December 1, 2011
    Applicant: Nippon Soda Co., Ltd.
    Inventors: Jyun Iwata, Masahiro Kawaguchi, Akiko Mizui